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Abstract
Aims/hypothesis The identification of novel targets that stim-
ulate endogenous regeneration of beta cells would represent a
significant advance in the treatment of patients with diabetes.
The betatrophin hypothesis suggests that increased expression
of angiopoietin-like protein 8 (ANGPTL8) induces dramatic
and specific beta cell proliferation and subsequent beta cell
mass expansion with improved glucose tolerance. In light of
recent controversy, we further investigated the effects of
ANGPTL8 overexpression on beta cell proliferation.
Methods We performed hydrodynamic tail vein injections of
green fluorescent protein (GFP) or Angptl8 (also known as
Gm6484) DNA in multiple cohorts of mice of different ages.
We employed state-of-the-art methods to comprehensively
quantify beta cell mass and proliferation, controlling for
mouse age, genetic strain, source of DNA injected, Angptl8
gene expression and proliferation markers.
Results In two young and two aged cohorts of B6.129 mice,
no substantial change in beta cell replication, mass or glucose
homeostasis was observed following ANGPTL8 overexpres-
sion. Even in mice with extremely elevated Angptl8
expression (26-fold increase), beta cell replication was not
significantly altered. Finally, we considered mice on the ICR
background exactly as studied by Melton and colleagues, and
still no beta cell mitogenic effect was detected following
ANGPTL8 overexpression.
Conclusion/interpretation ANGPTL8 does not stimulate beta
cell replication in young or old mice.
Keywords Ageing . ANGPTL8 . Betatrophin . Lipasin .
Lipid homeostasis . Pancreatic beta cell . RIFL
Abbreviations
ANGPTL8 Angiopoietin-like protein 8
EdU 5-Ethynyl-2′-deoxyuridine
GFP Green fluorescent protein
ITT Insulin tolerance test
PPx Partial pancreatectomy
Introduction
Diabetes is associated with reduced beta cell mass leading to
an absolute (type 1) or relative (type 2) insulin deficiency and
hyperglycaemia [1, 2]. Therapeutic islet transplantation suf-
fers from loss of glucose control over time and scarcity of
cadaveric islets. Stem cell generation of beta cells, while
progressing, has failed to phenocopy human beta cells [3].
Consequently, the field of beta cell biology continues to focus
on endogenous beta cell expansion. Normal beta cell growth
occurs by self-duplication, without the contribution of
specialised progenitor cells [4, 5]. Although putative beta cell
mitogens have been advanced, none has progressed as a dia-
betes therapy [6].
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Multiple studies suggest circulating factor(s) stimulate beta
cell proliferation in response to increased metabolic demand
[7–9]. Melton and colleagues administered insulin-receptor
antagonist S961 to mice in search of circulating factors [10].
Significant beta cell expansion occurred following insulin
receptor antagonism, and angiopoietin-like protein 8
(ANGPTL8) was highly upregulated in liver. ANGPTL8,
also known as lipasin/RIFL, was previously recognised as
a potent regulator of lipid metabolism [11–13]. Melton
and colleagues overexpressed ANGPTL8 in the livers of
ICR mice via hydrodynamic tail vein injection, inducing a
beta cell replication rate ∼17-fold greater than controls,
with a dramatic threefold expansion of beta cell area in
8 days and improved glucose tolerance [10]. They named
the gene betatrophin, as it appeared that ANGPTL8 ex-
panded beta cells via increased replication, furthering
ANGPTL8 as a candidate therapy for diabetes. The dis-
covery has been heralded as a major advance with the
potential to improve human health [14–16]. Confusingly,
ANGPTL8 levels are either increased or decreased in the
serum of type 2 diabetes patients [17–19].
The actions of ANGPTL8 on beta cell generation have
recently been called into question. Mice with knockout of
Angptl8 (also known as Gm6484) exhibited normal glucose
homeostasis [20]. Kaestner and colleagues reported that S961
administration stimulated beta cell replication in mouse but
not human islets, despite a fivefold increase in Angptl8
mRNA in liver [21]. However, the failure of ANGPTL8 over-
expression to induce beta cell replication in human islets in
this study could have been a consequence of its use of a het-
erologous species model [22].
Gromada and colleagues reported that beta cell area was
unaltered in Angptl8-knockout mice, even when challenged
with a high-fat diet or treated with S961 [23]. They also sug-
gest that ANGPTL8-overexpressing mice had no increase in
beta cell mass, although measurements were highly variable,
spanning a threefold range. Their data revealed a ∼30% in-
crease in beta cell mass (the difference was not reported to be
significant).
The Melton group published a reply providing data from
38 additional Angptl8-injected mice, asserting that some mice
show a ‘jackpot’ effect on beta cell replication [24]. Although
the magnitude of the response was smaller than previously
observed, beta cell proliferation was still significantly above
controls (p=0.016). Notably, the variability of beta cell
proliferation in ANGPTL8-overexpressing mice reported
by the Melton group is entirely consistent with the vari-
ability of beta cell mass observed by Gromada and col-
leagues. Thus, Melton and colleagues propose a hypothe-
sis in which the response to ANGPTL8 is highly variable,
and some mice have a strong beta cell response. We
aimed to definitively clarify the effects of ANGPTL8 on
beta cell proliferation.
Methods
Mice Male B6129SF1/J mice (JAX 101043) or retired male
breeders (JAX 101045) were obtained from Jackson Labs
(Bar Harbor, ME, USA). Male ICR mice were obtained from
Taconic (Germantown, NY, USA). Intraperitoneal GTTs were
performed on day 4 after a 16 h fast with 2 g D-glucose per kg.
Insulin tolerance tests (ITTs) were performed on day 6 after a
4 h fast with 0.5–1.0 U insulin (Humulin R; Eli Lilly,
Indianapolis, IN, USA) per kg. Mice were labelled continu-
ously via the drinking water with 5-ethynyl-2′-deoxyuridine
([EdU]; 0.5 g/l; Life Technologies, Grand Island, NY, USA)
from day 5 to 8. Mice were killed 8 days after injection for
beta cell morphometric analysis. Random fed serum samples
collected when the mice were killed were analysed for triac-
ylglycerol, cholesterol and VLDL. Serum insulin was mea-
sured by Mouse Ultrasensitive Insulin ELISA kit (Alpco
Diagnostics, Salem, NH, USA). B6.129 mice were fed 22%
kJ from fat (catalogue number 2919; Harlan Laboratories,
Houston, TX, USA). ICR mice were fed 16% kJ from fat
(2920; Harlan Labs) [10].
Hydrodynamic tail vein injection B6.129 male mice of 2, 8
and 16months of age or 7-week-old ICRmale mice were used
for hydrodynamic tail vein injections, as described previously
[10, 25–28]. Green fluorescent protein (GFP) or Angptl8 ex-
pression plasmid DNA (generous gifts from D. Melton,
Harvard University [10]), 100 mg, and sleeping beauty
transposase plasmid (pCMV-SB100X; Addgene, Cambridge,
MA, USA), 4 mg, were injected as 8% of body weight volume
(ml/g) over 5–7 s.
Partial pancreatectomy The splenic portion of pancreas was
removed as previously [5, 29, 30], resulting in a ∼50% pan-
createctomy (partial pancreatectomy [PPx]).
Immunohistochemistry and morphometry Paraffin sec-
tions for pancreatic head and tail were prepared as previously
described [30, 31]. The entire pancreas was sectioned every
200 μm, generating 8–16 sections for both head and tail pan-
creas. Primary antisera included guinea pig anti-insulin (cata-
logue number A0564, Dako, Carpinteria, CA, USA) and
mouse anti-human Ki67 (catalogue number 550609; BD
Biosciences, San Jose, CA, USA), followed by secondary
antisera conjugated to Cy3 or Cy5 (catalogue numbers 706-
166-148 and 715-605-151; Jackson ImmunoResearch
Laboratories, West Grove, PA, USA) and DAPI (Molecular
Probes, Eugene, OR, USA). EdU was detected by Click-iT
EDU Alexa Fluor 647 Imaging kit (Invitrogen, Carlsbad, CA,
USA). Images were acquired using Zeiss AxioImager (Carl
Zeiss MicroImaging, Thornwood, NY, USA) with Orca-ER
digital camera (Hamamatsu, Middlesex, NJ, USA). Slides
were imaged to quantify beta cell morphometry as previously
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described [30], using Volocity 6.1.1 software (PerkinElmer,
Waltham, MA, USA).
Proliferation analysis At least 4,000 (1,700 for partial pan-
createctomy) insulin+ cells were counted for Ki67. At least
2,900 (987 for partial pancreatectomy) insulin+ cells were
counted for EdU. Ki67+ or EdU+ beta cell ratios were calcu-
lated as per cent total insulin+ cells.
Real-time quantitative PCR Total mRNA was extracted
from liver using RNeasy Mini kit (Qiagen, Valencia, CA,
USA) and cDNA prepared using High Capacity Reverse
Transcription kit (Applied Biosystems, Foster City, CA,
USA). Real-time quantitative (q) dual fluorescent-labelled
fluorescence resonance energy transfer PCR (95°C 10 min,
40 cycles 95°C 15 s and 60°C 1 min) was performed with
ABI ViiA7 real-time PCR system (Applied Biosystems) to
amplify triplicate samples, comparing sample values with di-
lution curves. Relative gene product amounts are reported for
each gene normalised to cyclophilin. Native (endogenous)
Angptl8 primer/probes distinguish from total Angptl8 (exoge-
nous plus native). Primers/probes (electronic supplementary
material [ESM] Table 1) were purchased from Integrated
DNATechnologies (Coralville, IA, USA). Results from a sin-
gle experiment with technical replicates are averaged.
Statistics All data are mean±SEM, unless otherwise stated.
Results were compared with Student’s t test (unpaired) with a
Bonferroni correction when appropriate, reported as p values.
Study approval The study was approved by the Baylor
College of Medicine Institutional Animal Care and Use
Committee.
Results
ANGPTL8 overexpression has powerful biological effects
on lipids without any effect on glucose homeostasis in
young B6.129 mice Melton and colleagues identified
ANGPTL8 as a novel liver-derived protein that promotes beta
cell growth [10]. We overexpressed ANGPTL8 via hy-
drodynamic tail vein injection in 2-month-old B6.129
mice (Fig. 1a). Total Angptl8 gene expression increased
4.6-fold compared with GFP controls by qPCR (Fig. 1b,
ESM Table 2), equivalent to the threefold induction of
Angptl8 expression induced by the insulin receptor anta-
gonist S961 [10].
As ANGPTL8 was previously recognised as a potent reg-
ulator of lipid metabolism [11–13], we used serum lipid pro-
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biological effects on lipids
without any effect on glucose
homeostasis in young B6.129
mice. (a) Schematic indicating
time course of DNA injection,
GTT, ITT and killing of 2-month-
old B6.129 mice. (b) Total
Angptl8 gene expression analysis
was performed by qPCR on liver
samples, expressed as fold change
from GFP-injected mice with
cyclophilin used as control gene.
(c–f) Measurements of random
fed serum (c) triacylglycerol, (d)
cholesterol, (e) VLDL and (f)
blood glucose from GFP- or
Angptl8-injected mice. (g) GTTs
were performed on day 4, and (h)
ITTs (represented as % of initial
blood glucose) were performed
on day 6, fromGFP- and Angptl8-
injected mice. Mean±SEM, five
animals per group. *p<0.05 and
***p<0.001 vs GFP. White,
GFP-injected mice; black,
Angptl8-injected mice
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overexpression increased serum triacylglycerol and VLDL
levels compared with GFP-injected controls (Fig. 1c, e),
confirming biological activity of ANGPTL8. We then interro-
gated the impact of ANGPTL8 on glucose homeostasis.
Overexpression of ANGPTL8 did not alter random fed blood
glucose, glucose tolerance or insulin sensitivity (Fig. 1f–h;
detailed physiological data are shown in ESM Table 3).
Despite a powerful effect on lipids, ANGPTL8 had no effect
on glucose homeostasis.
ANGPTL8 overexpression does not alter beta cell area in
young B6.129 mice We used high-throughput quantitative
imaging methods to examine beta cell content throughout
the entire pancreas, sampling every 200 μm to obtain total
pancreas and insulin area (Fig. 2a, b). ANGPTL8 overexpres-
sion did not increase the cross-sectional insulin area or beta
cell area (% of total) compared with the GFP-injected group in
young B6.129 mice (Fig. 2c, d, ESM Table 4). These results
contrast with observations of a dramatic threefold increase in
beta cell area over the same time period reported by Melton
and colleagues [10].
ANGPTL8 overexpression does not alter beta cell prolif-
eration in young B6.129 mice Despite having no effect on
beta cell area, ANGPTL8 may still modestly increase prolif-
eration as recently reported [24]. Thus, we quantified beta cell
proliferation via Ki67 to determine if ANGPTL8 overexpres-
sion impacts beta cell replication (Fig. 3).
Beta cells expressing Ki67 were rare in both GFP- and
Angptl8-injected mice (Fig. 3b, c). In contrast, Ki67+ insulin+
cells were dramatically increased following partial pancreatec-
tomy ([PPx]; Fig. 3d, ESM Table 5), a well-established model
of beta cell proliferation [29, 30]. Quantification of Ki67+ beta
cell proliferation showed no effect of ANGPTL8 overexpres-
sion on replication, while PPx induced a threefold increase
over GFP controls (Fig. 3e).
Ki67 status gives a snapshot in time of beta cell repli-
cative events. Thus, we also performed thymidine ana-
logue (EdU) labelling over the final 3 days (Fig. 3a).
Equally low levels of EdU incorporation were observed
in beta cells of GFP and Angptl8 groups (Fig. 3f, g).
ANGPTL8 overexpression had no effect on the percentage
of EdU+ beta cells, although proliferation was significant
in the head pancreases of partially pancreatectomised mice
(Fig. 3f–i, ESM Table 5). These results indicate that
ANGPTL8 does not increase beta cell replication in young
B6.129 mice, especially in relation to PPx, a potent induc-
er of beta cell proliferation.
ANGPTL8 expression in young mice We considered that
our findings could be confounded by using the wrong strain/
age of mice or achieving an insufficient level of ANGPTL8
overexpression. Consequently we expanded our analysis to
include a second cohort of 2-month-old B6.129 mice, two
additional aged B6.129 cohorts (8- and 16-month-old), and
young ICR mice (the exact strain and source of mice
employed by Melton and colleagues [10]). Our initial qPCR
primer/probe set measured total Angptl8 (exogenous and en-
dogenous), thus we developed tools to quantify native
(endogenous) Angptl8 gene expression.
Total Angptl8 expression was increased sixfold in the sec-
ond cohort of 2-month B6.129 mice compared with GFP
(Fig. 4b). This increase in expression was threefold higher
than the original cohort of Angptl8-injected mice and 16-fold
in absolute Angptl8 mRNA levels compared with controls for
our first cohort. Native Angptl8 mRNA expression was un-
changed by ANGPTL8 overexpression in both cohorts of
2-month-old B6.129 mice, indicating that the exogenous
Angptl8 entirely contributed to the increase in total Angptl8
(Fig. 4b, c, ESM Table 2).
We also examined the impact of ANGPTL8 overexpres-
sion in young ICR mice. Total Angptl8 was increased by 3.2-
fold compared with GFP, with no change in native Angptl8
(Fig. 4b, c). Thus, we were able to overexpress Angptl8 in the








































Fig. 2 ANGPTL8 overexpression does not alter beta cell area. (a, b)
Representative low-power images of total pancreas (green) and total in-
sulin area (red) for (a) GFP and (b) Angptl8 DNA-injected 2-month-old
B6.129 mice. Scale bars: 2 mm. (c) For each mouse we analysed 10–12
pancreatic sections per head or tail region, and plotted the cross-sectional
insulin area for each pancreatic section as a single dot within a vertical
column. Black dots, GFP; grey dots, Angptl8. (d) Beta cell area (% of
total pancreas) for the head, tail and total pancreas. Circles, GFP; squares,
Angptl8. Mean±SEM, five animals per group
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ANGPTL8 overexpression reduces native Angptl8 expres-
sion in agedmice We injected GFP or Angptl8 into 8- and
16-month-old B6.129 mice to examine the age-related im-
pact of exogenous Angptl8 overexpression. Control aged
mice exhibited ∼tenfold increase in native Angptl8 expres-
sion compared with mice at 2 months (p<0.05; Fig. 4c,
ESM Table 2). Surprisingly, total Angptl8 expression was
unchanged in aged mice injected with Angptl8, while na-
tive Angptl8 expression was reduced (Fig. 4b, c). This
result suggests that counter-regulatory feedback loops pre-
serve Angptl8 expression at a constant level in older mice.
If such counter-regulatory loops protect Angptl8 expression
levels, this could challenge the potential therapeutic utility
of interventions to augment Angptl8 expression in type 2
diabetes.
ANGPTL8 overexpression does not alter beta cell area in
B6.129 mice of various ages or in ICR mice We performed
extensive morphometric analysis of the entire pancreas using
high-throughput image processing to quantify beta cells (ESM
Figs 1 and 2, ESM Table 4). Insulin area, quantified as cross-
sectional or cumulative total, was largely unchanged by
ANGPTL8 overexpression in B6.129 mice at any age or in
ICRmice (ESMFig. 2a–h). Aminimal increase in insulin area
was observed in the tail of the additional 2-month-old B6.129
group (ESM Fig. 2e). Given the tiny magnitude of this
difference, it likely represents the precision with which
our techniques can detect small changes in biological
variation as opposed to the physiological intervention
of ANGPTL8 overexpression. Cumulative total pancreas
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overexpression does not alter beta
cell proliferation in young B6.129
mice. (a) Schematic indicating
time course for DNA injection or
PPx, with EdU labelling from day
5 to 8. Immunostaining for (b–d)
Ki67 (red), insulin (green) and
DAPI (blue) for (b) GFP, (c)
Angptl8 and (d) PPx groups
(2-month-old B6.129 mice). (e)
Quantification of beta cell
proliferation measured by Ki67+
insulin+ cells as a percentage of
total insulin+ cells for total
pancreas. Immunostaining for
(f–h) EdU (red), insulin (green)
and DAPI (blue) for (f) GFP, (g)
Angptl8 and (h) PPx groups
(2-month-old B6.129 mice). (i)
Quantification of beta cell
proliferation measured by EdU+
insulin+ cells as a percentage of
total insulin+ cells in the head, tail
and total pancreas. Scale bars:
100μm.Mean±SEM, four to five
animals per group. **p<0.01 and
***p<0.001 vs GFP
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Total pancreatic beta cell area and mass were equivalent
between GFP and ANGPTL8 for all four cohorts (Fig. 5a,
ESM Fig. 2m–t). Thus, we were unable to confirm prior re-
ports [10] of massive beta cell expansion by ANGPTL8 in our
studies with multiple cohorts of mice at various ages, includ-
ing strain-matched young ICR mice.
ANGPTL8 overexpression does not alter beta cell prolif-
eration in B6.129mice of various ages or in ICRmice Beta
cell proliferation in the additional cohort of 2-month-old
B6.129 mice (which expressed extremely high levels of
Angptl8) was unaltered by Ki67 or EdU (Fig. 5b, ESM
Figs 3 and 4, ESM Table 5). Beta cell proliferation was equiv-
alent between GFP and ANGPTL8 groups in older mice. As
expected, beta cell proliferation was potently increased by
PPx in 2- and 8-month-old mice. ANGPTL8 overexpression
had no effect on beta cell proliferation in young ICR mice,
unlike PPx. Thus, we conclude that ANGPTL8 does not stim-
ulate beta cell replication.
Discussion
Although Melton and colleagues recently asserted that ANGP
TL8 overexpression variably increases beta cell proliferation,
we show here that ANGPTL8 overexpression in mice does not
alter beta cell proliferation. We attempted to replicate the orig-
inal and additional ANGPTL8 overexpression studies [10, 23,
24], including multiple cohorts of mice quantified with ad-
vanced imaging modalities. We carried out rigorous analysis
of beta cell replication with both Ki67 and EdU, demonstrating
that ANGPTL8 does not stimulate beta cell proliferation.
Mouse genetic strain and age could influence putative beta
cell trophic actions of ANGPTL8, therefore we included an
array of strains and ages. Moreover, we used the Melton
Angptl8 plasmid [10]. Our initial studies in 2-month-old
B6.129 mice suggested that ANGPTL8 overexpression does
not expand beta cells. We then overexpressed ANGPTL8 in a
second cohort of 2-month-old B6.129 mice. For reasons that
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Fig. 4 Native Angptl8 increases with age and is reduced in aged mice
following overexpression of exogenous Angptl8. (a) Schematic indicat-
ing time course for two cohorts of 2-, 8- and 16-month-old B6.129 mice
and 2-month-old ICR mice. (b) Total and (c) native Angptl8 gene expres-
sion analysis was performed by qPCR on liver samples, expressed as fold
change from original 2-month-old GFP-injected B6.129 mice with
cyclophilin used as control gene. The original 2-month B6.129 cohort is
listed first in each graph (furthest left) followed by a second 2-month
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Fig. 5 ANGPTL8 overexpression does not alter beta cell mass or prolif-
eration in B6.129 mice of various ages or ICR mice. (a) Total beta cell
mass and (b) total beta cell proliferation measured as Ki67+ insulin+ cells
(% of total insulin+ cells) in GFP, Angptl8 and PPx groups. Cohorts
include a second group of 2-month-old B6.129 mice, 8- and 16-month-
old B6.129 mice and 2-month-old ICR mice. Mean±SD, five to eight
animals per group. White bars, GFP; black bars, Angptl8; hatched bars,
PPx
1528 Diabetologia (2015) 58:1523–1531
vastly exceeded other cohorts (up to 26-fold that of controls in
two mice). This additional cohort therefore allowed us to rig-
orously test the betatrophin hypothesis, assuming higher
Angptl8 expression might lead to greater stimulation of beta
cell area or proliferation. However, even extreme Angptl8 ex-
pression had no effect on beta cell expansion.
Control mice at 8 and 16months of age had higher levels of
Angptl8 expression than young control mice. However, aged
mice, despite their higher levels of Angptl8 expression, had far
less beta cell proliferation than younger mice. Thus, even our
aged controls challenge the betatrophin hypothesis.
Last, we considered the possibility that genetic strain dif-
ferences could explain the lack of response in B6.129 mice.
We administered Angptl8 to young ICR male mice, as per-
formed by Melton and colleagues [10], but again found no
change in beta cell proliferation. Gromada and colleagues
did not match the Melton strain, age and DNA, leaving their
results open to criticism that unforeseen variables could have
influenced the regenerative response [23]. The reason for the
discrepancy between our results and those of Melton and col-
leagues is not clear. However, here we have controlled for
experimental conditions, matching those used by the Melton
group, and conclude that ANGPTL8 overexpression has no
effect on beta cell proliferation or area.
Insufficient or inappropriate sampling of beta cells could
introduce unwanted variability and bias, rendering the subse-
quent data uninterpretable. To avoid erroneous sampling from
regions of the pancreas rich in beta cells, we divided the pan-
creas into head and tail, sectioning every 200 μm from top to
bottom. This method resulted in 8–16 sections per pancreas
portion, allowing for a comprehensive analysis of pancreatic
beta cell area (complete raw data are in ESM Table 4).
We were concerned about the possibility of proliferating
intra-islet non-beta cells contaminating our process to quantify
beta cell proliferation (as previously examined [30]). As a result,
we exclusively imaged islets with a ×40 high numerical aperture
objective (0.70) to ensure beta cells (and not other cells) were
correctly identified within islets. As proliferative events marked
by Ki67 may be rare and highly variable, we counted at least 4,
000 beta cells per pancreas in GFP- and Angptl8-injected mice
(complete raw data in ESMTable 5). Similarly, we counted over
2,900 beta cells to quantify EdU-labelled beta cells. Thus, we
are confident that we have correctly assessed any potential
changes in beta cell area/proliferation, and demonstrate minimal
variability in beta cell area/proliferation across all cohorts, with
no significant change in ANGPTL8-overexpressing mice.
Our studies included PPx as a positive control for beta cell
proliferation in order to put the putative trophic effect of
ANGPTL8 in the context of other known beta cell mitogenic
stimuli. PPx is well documented to induce beta cell prolifera-
tion [29, 30]. As expected, PPx induced beta cell replication
by three- to fivefold in young B6.129 and ICR mice.
However, ANGPTL8 overexpression had no effect on beta
cell replication. A regenerative response to PPx was main-
tained at 8 months of age but declined by 16 months, corrob-
orating previous studies demonstrating an age-related decline
in adaptive beta cell proliferation [29]. Even though beta cells
remained responsive to regenerative stimuli at 8 months of
age, no such response was observed with ANGPTL8 overex-
pression in mice at 8 or 16 months.
The large number of biological replicates allows us to test
the ‘jackpot’ hypothesis recently advanced by Melton and
colleagues [24], whereby some mice respond strongly to
ANGPTL8 but many others do not. In this scenario, occasion-
al mice would have extreme beta cell proliferation compared
with their peers because of intrinsic differences caused by
some unidentified variable. To address the possibility of a
variable jackpot response, we carried out our studies in a large
number of mice (28 controls and 31 experimental animals).
We quantified beta cell proliferation with Ki67 (as performed
by Melton and colleagues with great variability) and long-
term EdU labelling to aid precise measurement of beta cell
proliferation. However, no proliferative response to ANGP
TL8 expression was observed, with little intrinsic variation
in beta cell proliferation within mice. The largest variability
occurred in the original 2-month-old B6.129 cohort; beta cell
proliferation in one mouse was 0.5% with Ki67 while another
mouse was 0.12% (ESM Table 5). Young ICR Angptl8-
injected mice had EdU+ replication rates that peaked at
7.67% and 7.29% (identified as 325.1Wand 325.4W, respec-
tively), which was comparable with the highest beta cell pro-
liferation in the control GFP group (7.17%, identified as
323.3 W; ESM Table 5).
The lack of intrinsic variability in beta cell response to
ANGPTL8 is in sharp contrast to the highly variable beta cell
proliferation results ofMelton and colleagues, and the variable
beta cell mass observed by Gromada and colleagues [10, 23,
24]. The absolute values and equally small variability across
all cohorts are inconsistent with the hypothesis that a subset of
mice potently respond to ANGPTL8 overexpression. Instead,
it seems likely that any variation previously attributed to con-
tribute to a jackpot hypothesis might be the result of under-
sampling or technical differences in between cohorts (such as
variable age of mice tested). Taken together, these results
strongly oppose the premise that some mice respond strongly
to ANGPTL8 overexpression.
A final potential confounding factor to consider is the ex-
pression level of Angptl8 necessary to induce beta cell prolif-
eration. Previous reports did not quantify Angptl8 gene ex-
pression following hydrodynamic tail vein injection [10, 23,
24]. Liver Angptl8 was increased by ∼4.5-fold in NOD severe
combined immunodeficiency (SCID) mice and threefold in
ICR mice following 7 days of S961 treatment and was asso-
ciated with an extraordinary amount of beta cell proliferation
(>20- and 12-fold) [10, 21]. These expression values are
equivalent to those found in our studies, with total Angptl8
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increasing by 3.2-fold and 4.6-fold in ICR and B6.129 mice,
respectively. Importantly, our second cohort of Angptl8-
injected mice had extremely high levels of Angptl8 expression
(sixfold vs GFP and 16-fold compared with controls of our
first cohort), but no increase in beta cell proliferation.
In summary, we show that ANGPTL8 overexpression does
not increase beta cell proliferation. Melton and colleagues
initially reported that exogenous Angptl8 induced massive be-
ta cell expansion by threefold within 8 days [10]. Gromada
and colleagues recently reported that ANGPTL8 does not
control beta cell expansion [23]. Notably, Gromada and col-
leagues did not quantify beta cell proliferation. Confusingly,
Melton and colleagues responded that ANGPTL8 overexpres-
sion increased beta cell replication [24]. However, we provide
studies in multiple cohorts of mice of various ages and genetic
strains, employing the most rigorous methods in current use to
quantify beta cells, finding that ANGPTL8 overexpression
does not alter beta cell proliferation or expansion.
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